Flash Sell! Cash in on an 80% Profit on This Ophthalmology Specialist
We picked up shares immediately after a sharp 70% drop in May of last year. The driver was data from a clinical trial that didn't show the drug worked better than a comparator overall. However, when I dug further into the trial data I noticed that the drug worked in 80% of patients who had lower eye pressures. The company had an additional Phase 3 in progress, and it had a shot at getting the FDA to sign on for modifying it to focus on this patient group. This is exactly what ended up happening and it paid off…
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.